Radiolabeled Nanocarriers as Theranostics-Advancement from Peptides to Nanocarriers.
biodistribution
cancer
molecular imaging
peptide receptor radionuclide therapy
toxicity
Journal
Small (Weinheim an der Bergstrasse, Germany)
ISSN: 1613-6829
Titre abrégé: Small
Pays: Germany
ID NLM: 101235338
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
15
04
2022
received:
31
01
2022
pubmed:
9
5
2022
medline:
25
6
2022
entrez:
8
5
2022
Statut:
ppublish
Résumé
Endogenous targeted radiotherapy is emerging as an integral modality to treat a variety of cancer entities. Nevertheless, despite the positive clinical outcome of the treatment using radiolabeled peptides, small molecules, antibodies, and nanobodies, a high degree of hepatotoxicity and nephrotoxicity still persist. This limits the amount of dose that can be injected. In an attempt to mitigate these side effects, the use of nanocarriers such as nanoparticles (NPs), dendrimers, micelles, liposomes, and nanogels (NGs) is currently being explored. Nanocarriers can prolong circulation time and tumor retention, maximize radiation dosage, and offer multifunctionality for different targeting strategies. In this review, the authors first provide a summary of radiation therapy and imaging and discuss the new radiotracers that are used preclinically and clinically. They then highlight and identify the advantages of radio-nanomedicine and its potential in overcoming the limitations of endogenous radiotherapy. Finally, the review points to the ongoing efforts to maximize the use of radio-nanomedicine for efficient clinical translation.
Identifiants
pubmed: 35527333
doi: 10.1002/smll.202200673
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Micelles
0
Peptides
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200673Informations de copyright
© 2022 The Authors. Small published by Wiley-VCH GmbH.
Références
a) Y. Liu, P. Zhang, F. Li, X. Jin, J. Li, W. Chen, Q. Li, Theranostics 2018, 8, 1824;
b) R. Baskar, K. A. Lee, R. Yeo, K. W. Yeoh, Int. J. Med. Sci. 2012, 9, 193.
D. Hoegler, Curr. Probl. Cancer 1997, 21, 129.
O. Palata, N. H. Podzimkova, E. Nedvedova, A. Umprecht, L. Sadilkova, L. P. Jelinkova, R. Spisek, I. Adkins, Front. Oncol. 2019, 9, 367.
a) M. T. K. Helen, H. W. Chen, Oncotarget 2017, 8, 62742;
b) M. Baumann, M. Krause, J. Overgaard, J. Debus, S. M. Bentzen, J. Daartz, C. Richter, D. Zips, T. Bortfeld, Nat. Rev. Cancer 2016, 16, 234;
c) R. Morrison, S. M. Schleicher, Y. Sun, K. J. Niermann, S. Kim, D. E. Spratt, C. H. Chung, B. Lu, J. Oncol. 2011, 2011, 1;
d) A. C. Begg, F. A. Stewart, C. Vens, Nat. Rev. Cancer 2011, 11, 239;
e) M. Grzmil, A. Meisel, M. Behé, R. Schibli, in Radiopharmaceutical Chemistry, Vol. 1, (Eds: J. Lewis, A. Windhorst, B. Zeglis), Springer, Cham 2019, pp. 85-100.
S. Mehta, V. Suhag, M. Semwal, N. Sharma, Med. J. Armed Forces India 2010, 66, 158.
B. J. Stish, B. J. Davis, L. A. Mynderse, R. H. McLaren, C. L. Deufel, R. Choo, Transl. Androl. Urol. 2018, 7, 341.
J. Skowronek, J. Contemp. Brachyther. 2017, 9, 581.
H.-J. Wester, Clin. Cancer Res. 2007, 13, 3470.
A. Yordanova, E. Eppard, S. Kürpig, R. A. Bundschuh, S. Schönberger, M. Gonzalez-Carmona, G. Feldmann, H. Ahmadzadehfar, M. Essler, OncoTargets Ther. 2017, 10, 4821.
I. Velikyan, Theranostics 2012, 2, 424.
F. M. Lu, Z. Yuan, Quant. Imaging Med. Surg. 2015, 5, 433.
H. Jadvar, AJR, Am. J. Roentgenol. 2017, 209, 277.
a) M. Van Essen, E. P. Krenning, B. L. Kam, M. De Jong, R. Valkema, D. J. Kwekkeboom, Nat. Rev. Endocrinol. 2009, 5, 382;
b) M. Öksüz, L. Winter, C. Pfannenberg, G. Reischl, K. Müssig, R. Bares, H. Dittmann, Diagn. Interventional Imaging 2014, 95, 289;
c) H. R. Kulkarni, R. P. Baum, PET Clin. 2014, 9, 83;
d) G. Kong, M. S. Hofman, W. K. Murray, S. Wilson, P. Wood, P. Downie, L. Super, A. Hogg, P. Eu, R. J. Hicks, J. Pediatr. Hematol./Oncol. 2016, 38, 87.
a) Z. Wang, R. Tian, G. Niu, Y. Ma, L. Lang, L. P. Szajek, D. O. Kiesewetter, O. Jacobson, X. Chen, Bioconjugate Chem. 2018, 29, 3213;
b) M. Weineisen, M. Schottelius, J. Simecek, R. P. Baum, A. Yildiz, S. Beykan, H. R. Kulkarni, M. Lassmann, I. Klette, M. Eiber, J. Nucl. Med. 2015, 56, 1169;
c) M. Benešová, M. Schäfer, U. Bauder-Wüst, A. Afshar-Oromieh, C. Kratochwil, W. Mier, U. Haberkorn, K. Kopka, M. Eder, J. Nucl. Med. 2015, 56, 914.
M. Kircher, P. Herhaus, M. Schottelius, A. K. Buck, R. A. Werner, H.-J. Wester, U. Keller, C. Lapa, Ann. Nucl. Med. 2018, 32, 503.
M. Pacilio, G. Ventroni, G. De Vincentis, B. Cassano, R. Pellegrini, E. Di Castro, V. Frantellizzi, G. A. Follacchio, T. Garkavaya, L. Lorenzon, Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 21.
D. L. Thomas, Y. Menda, D. Bushnell, Clin. Nucl. Med. 2009, 34, 745.
a) F. Liu, H. Zhu, J. Yu, X. Han, Q. Xie, T. Liu, C. Xia, N. Li, Z. Yang, Tumor Biol. 2017, 39, 1010428317705519;
b) R. A. Werner, C. Bluemel, M. S. Allen-Auerbach, T. Higuchi, K. Herrmann, Ann. Nucl. Med. 2015, 29, 1.
S. U. Dalm, I. L. Bakker, E. de Blois, G. N. Doeswijk, M. W. Konijnenberg, F. Orlandi, D. Barbato, M. Tedesco, T. Maina, B. A. Nock, J. Nucl. Med. 2017, 58, 293.
a) T. Huynh, E. Van Dam, Z. Houston, L. McInnes, C. Mpoy, M. Harris, K. Thurecht, P. Donnelly, B. Rogers, Soc. Nucl. Med. 2021, 62, 1237;
b) L. McInnes, N. Zia, C. Cullinane, J. Van Zuylekom, S. Jackson, J. Stoner, M. Haskali, P. Roselt, E. Van Dam, M. Harris, Soc. Nucl. Med. 2020, 61, 1215.
a) P. Blower, A. Kettle, M. O'doherty, A. Coakley, F. Knapp Jr., Eur. J. Nucl. Med. 2000, 27, 1405;
b) J. Mukiza, E. Byamukama, J. Sezirahiga, K. Ngbolua, V. Ndebwanimana, Rwanda Med. J. 2018, 75, 14.
a) S. Kalimuthu, J. H. Jeong, J. M. Oh, B. C. Ahn, Int. J. Mol. Sci. 2017, 18, 1639;
b) A. Hyatt, J. Radiother. Pract. 2009, 8, 165;
c) S. F. Mirshojaei, A. Ahmadi, E. Morales-Avila, M. Ortiz-Reynoso, H. Reyes-Perez, J. Drug Targeting 2016, 24, 91.
L. Livieratos, in Radionuclide and Hybrid Bone Imaging (Eds: I. Fogelman, G. Gnanasegaran, H. van der Wall), Springer, Berlin, Heidelberg 2012, pp. 345-359.
R. L. Cazzato, J. Garnon, B. Shaygi, G. Koch, G. Tsoumakidou, J. Caudrelier, P. Addeo, P. Bachellier, I. J. Namer, A. Gangi, Minimally Invasive Ther. Allied Technol. 2018, 27, 27.
a) M. M. Khalil, J. L. Tremoleda, T. B. Bayomy, W. Gsell, Int. J. Mol. Imaging 2011, 2011, 796025;
b) S. Adak, R. Bhalla, K. K. V. Raj, S. Mandal, R. Pickett, S. K. Luthra, Radiochim. Acta 2012, 100, 95;
c) S. L. Pimlott, A. Sutherland, Chem. Soc. Rev. 2011, 40, 149;
d) L. Jødal, C. Le Loirec, C. Champion, Phys. Med. Biol. 2014, 59, 7419;
e) E. L. Cole, M. N. Stewart, R. Littich, R. Hoareau, P. J. H. Scott, Curr. Top. Med. Chem. 2014, 14, 875.
S. Srivastava, L. Mausner, R. Mease, 1991, https://www.osti.gov/servlets/purl/5332217.
P. Y. Keng, M. Sergeev, R. M. van Dam, in Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy, Vol. 1 (Eds: Y. Kuge, T. Shiga, N. Tamaki), Springer, Tokyo, Japan 2016, p. 93.
U. Haberkorn, F. Giesel, A. Morgenstern, C. Kratochwil, J. Nucl. Med. 2017, 58, 1017.
J.-P. Pouget, I. Navarro-Teulon, M. Bardiès, N. Chouin, G. Cartron, A. Pèlegrin, D. Azria, Nat. Rev. Clin. Oncol. 2011, 8, 720.
M. Brandt, J. Cardinale, M. L. Aulsebrook, G. Gasser, T. L. Mindt, J. Nucl. Med. 2018, 59, 1500.
N. Drude, L. Tienken, F. M. Mottaghy, Methods 2017, 130, 14.
V. Carroll, D. W. Demoin, T. J. Hoffman, S. S. Jurisson, Radiochim. Acta 2012, 100, 653.
N. Raj, D. Reidy-Lagunes, Pancreas 2018, 47, 1.
S. Basu, R. V. Parghane, S. Banerjee, Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 756.
U. Hennrich, K. Kopka, Pharmaceuticals 2019, 12, 114.
a) Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs), https://ClinicalTrials.gov/show/NCT04334837 (accessed: April 2020);
b) Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE, https://ClinicalTrials.gov/show/NCT03673943 (accessed: September 2018).
U. Hennrich, M. Benešová, Pharmaceuticals 2020, 13, 38.
L. Kabasakal, E. Demirci, M. Ocak, C. Decristoforo, A. Araman, Y. Ozsoy, I. Uslu, B. Kanmaz, Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1271.
I. Y. F. Mak, A. R. Hayes, B. Khoo, A. Grossman, Neuroendocrinology 2019, 109, 287.
C. Jimenez, R. Grewal, G. Ravizzini, B. Chin, M. Pampaloni, K. Matthay, J. Jensen, T. Lin, S. Apfel, T. White, J. Endocr. Soc. 2019, 3, https://europepmc.org/articles/PMC6553226.
FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer, https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer (accessed: December 2020).
S. Hertz, A. Roberts, J. Means, R. Evans, Am. J. Physiol. 1940, 128, 565.
a) M. Schmidt, B. Hero, T. Simon, Clin. Transl. Imaging 2016, 4, 87;
b) R. A. Schoot, G. Bleeker, H. N. Caron, B. L. van Eck, H. A. Heij, J. de Kraker, G. A. Tytgat, Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 1516.
C. Jimenez, W. Erwin, B. Chasen, Cancers 2019, 11, 1018.
A. N. Van Der Horst-Schrivers, P. L. Jager, H. M. Boezen, J. P. Schouten, I. P. Kema, T. P. Links, Anticancer Res. 2006, 26, 1599.
a) J. W. Lenders, Q.-Y. Duh, G. Eisenhofer, A.-P. Gimenez-Roqueplo, S. K. Grebe, M. H. Murad, M. Naruse, K. Pacak, W. F. Young Jr., J. Clin. Endocrinol. Metab. 2014, 99, 1915;
b) C. A. Chang, D. A. Pattison, R. W. Tothill, G. Kong, T. J. Akhurst, R. J. Hicks, M. S. Hofman, Cancer Imaging 2016, 16, 22;
c) J. Maurice, R. Troke, Z. Win, R. Ramachandran, A. Al-Nahhas, M. Naji, W. Dhillo, K. Meeran, A. Goldstone, N. Martin, Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1266.
D. A. Silver, I. Pellicer, W. R. Fair, W. Heston, C. Cordon-Cardo, Clin. Cancer Res. 1997, 3, 81.
E. Gourni, G. Henriksen, Molecules 2017, 22, 523.
a) C. Kratochwil, F. Bruchertseifer, F. L. Giesel, M. Weis, F. A. Verburg, F. Mottaghy, K. Kopka, C. Apostolidis, U. Haberkorn, A. Morgenstern, J. Nucl. Med. 2016, 57, 1941;
b) S. Satapathy, A. Sood, C. K. Das, B. R. Mittal, Prostate Cancer Prostatic Dis. 2021, 24, 880.
C. Xu, H. Zhang, Biomed Res. Int. 2015, 2015, 1.
a) L. Bodei, M. Cremonesi, C. Grana, P. Rocca, M. Bartolomei, M. Chinol, G. Paganelli, Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1038;
b) C. Waldherr, M. Pless, H. R. Maecke, T. Schumacher, A. Crazzolara, E. U. Nitzsche, A. Haldemann, J. Mueller-Brand, J. Nucl. Med. 2002, 43, 610;
c) D. J. Kwekkeboom, W. H. Bakker, P. P. Kooij, M. W. Konijnenberg, A. Srinivasan, J. L. Erion, M. A. Schmidt, J. L. Bugaj, M. de Jong, E. P. Krenning, Eur. J. Nucl. Med. 2001, 28, 1319;
d) S. Ezziddin, M. Attassi, C. J. Yong-Hing, H. Ahmadzadehfar, W. Willinek, F. Grünwald, S. Guhlke, H.-J. Biersack, A. Sabet, J. Nucl. Med. 2014, 55, 183.
A. I. Kassis, Semin. Nucl. Med. 2008, 38, 358.
L. Bodei, D. J. Kwekkeboom, M. Kidd, I. M. Modlin, E. P. Krenning, Semin. Nucl. Med. 2016, 46, 225.
T. L. Andersen, C. Baun, B. B. Olsen, J. H. Dam, H. Thisgaard, J. Nucl. Med. 2020, 61, 228.
H. Junde, Nucl. Data Sheets 2008, 109, 787.
B. Singh, Nucl. Data Sheets 2007, 108, 197.
a) L. Baratto, H. Jadvar, A. Iagaru, Mol. Imaging Biol. 2018, 20, 501;
b) D. Pooja, A. Gunukula, N. Gupta, D. J. Adams, H. Kulhari, Int. J. Biochem. Cell Biol. 2019, 114, 105567.
C. Kratochwil, F. Giesel, F. Bruchertseifer, W. Mier, C. Apostolidis, R. Boll, K. Murphy, U. Haberkorn, A. Morgenstern, Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 2106.
G. Vauquelin, I. Van Liefde, Trends Pharmacol. Sci. 2006, 27, 355.
D. Reidy-Lagunes, N. Pandit-Taskar, J. A. O'Donoghue, S. Krebs, K. D. Staton, S. K. Lyashchenko, J. S. Lewis, N. Raj, M. Gönen, C. Lohrmann, Clin. Cancer Res. 2019, 25, 6939.
R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, J. C. Reubi, J. Nucl. Med. 2008, 49, 318.
J. Kurth, B. J. Krause, S. M. Schwarzenböck, C. Bergner, O. W. Hakenberg, M. Heuschkel, Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 123.
Phase 1 Study of AlphaMedixTM in Adult Subjects With SSTR (+) NET, https://ClinicalTrials.gov/show/NCT03466216 (accessed: March 2018).
S. Ballal, M. P. Yadav, C. Bal, R. K. Sahoo, M. Tripathi, Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 934.
C. Bal, M. Yadav, S. Ballal, M. Tripathi, Soc. Nucl. Med. 2020, 61, 416.
a) C. Rangger, R. Haubner, Pharmaceuticals 2020, 13, 22;
b) G. Ting, C. H. Chang, H. E. Wang, T. W. Lee, J. Biomed. Biotechnol. 2010, 2010, 1.
a) J.-W. Yoo, E. Chambers, S. Mitragotri, Curr. Pharm. Des. 2010, 16, 2298;
b) P. Desai, R. Rimal, A. Florea, R. A. Gumerov, M. Santi, A. S. Sorokina, S. E. Sahnoun, T. Fischer, F. M. Mottaghy, A. Morgenroth, Angew. Chem., Int. Ed. 2022, 61, e2021166.
a) L. Farzin, S. Sheibani, M. E. Moassesi, M. Shamsipur, J. Biomed. Mater. Res., Part A 2019, 107, 251;
b) T. T. J. Garcia, A. Y. Louie, Nanomedicine 2015, 10, 1343.
M. Benezra, O. Penate-Medina, P. B. Zanzonico, D. Schaer, H. Ow, A. Burns, E. DeStanchina, V. Longo, E. Herz, S. Iyer, J. Clin. Invest. 2011, 121, 2768.
A. L. de Barros, K. S. de Oliveira Ferraz, T. C. Dantas, G. F. Andrade, V. N. Cardoso, E. M. Sousa, Mater. Sci. Eng., C 2015, 56, 181.
M. Radović, M. P. Calatayud, G. F. Goya, M. R. Ibarra, B. Antić, V. Spasojević, N. Nikolić, D. Janković, M. Mirković, S. Vranješ-Đurić, J. Biomed. Mater. Res., Part A 2015, 103, 126.
H. Y. Lee, Z. Li, K. Chen, A. R. Hsu, C. Xu, J. Xie, S. Sun, X. Chen, J. Nucl. Med. 2008, 49, 1371.
X. Yang, H. Hong, J. J. Grailer, I. J. Rowland, A. Javadi, S. A. Hurley, Y. Xiao, Y. Yang, Y. Zhang, R. J. Nickles, Biomaterials 2011, 32, 4151.
E. A. Salvanou, D. Stellas, C. Tsoukalas, B. Mavroidi, M. Paravatou-Petsotas, N. Kalogeropoulos, S. Xanthopoulos, F. Denat, G. Laurent, R. Bazzi, S. Roux, P. Bouziotis, Pharmaceutics 2020, 12, 188.
W. Cai, K. Chen, Z. B. Li, S. S. Gambhir, X. Chen, J. Nucl. Med. 2007, 48, 1862.
a) A. N. A. Mitra, B. R. Line, H. Ghandehari, Curr. Pharm. Des. 2006, 12, 4729;
b) M. Hamoudeh, M. A. Kamleh, R. Diab, H. Fessi, Adv. Drug Delivery Rev. 2008, 60, 1329.
D.-E. Lee, J. H. Na, S. Lee, C. M. Kang, H. N. Kim, S. J. Han, H. Kim, Y. S. Choe, K.-H. Jung, K. C. Lee, K. Choi, I. C. Kwon, S. Y. Jeong, K.-H. Lee, K. Kim, Mol. Pharmaceutics 2013, 10, 2190.
H. Rajabi, S. Rasaneh, S. Salehi, Synth. React. Inorg., Met.-Org., Nano-Met. Chem. 2016, 46, 1450.
T. Banerjee, A. K. Singh, R. K. Sharma, A. N. Maitra, Int. J. Pharm. 2005, 289, 189.
G. Arora, J. Shukla, S. Ghosh, S. K. Maulik, A. Malhotra, G. Bandopadhyaya, PLoS One 2012, 7, e34019.
G. Arora, P. Dubey, J. Shukla, S. Ghosh, G. Bandopadhyaya, Ann. Nucl. Med. 2016, 30, 334.
R. M. Kruijff, R. Raave, A. Kip, J. Molkenboer-Kuenen, A. Morgenstern, F. Bruchertseifer, S. Heskamp, A. G. Denkova, Sci. Rep. 2019, 9, 11671.
F. Man, T. Lammers, R. T. de Rosales, Mol. Imaging Biol. 2018, 20, 683.
H. Lee, A. F. Shields, B. A. Siegel, K. D. Miller, I. Krop, C. X. Ma, P. M. LoRusso, P. N. Munster, K. Campbell, D. F. Gaddy, Clin. Cancer Res. 2017, 23, 4190.
a) S. Stewart, K. J. Harrington, Oncology 1997, 11, 33;
b) K. J. Harrington, S. Mohammadtaghi, P. S. Uster, D. Glass, A. M. Peters, R. G. Vile, J. S. W. Stewart, Clin. Cancer Res. 2001, 7, 243.
J. Kousalova, T. Etrych, Physiol. Res. 2018, 67, S305.
K. S. Soni, S. S. Desale, T. K. Bronich, J. Controlled Release 2016, 240, 109.
M. E. Napier, J. M. DeSimone, J. Macromol. Sci., Polym. Rev. 2007, 47, 321.
M. Chan, A. Almutairi, Mater. Horiz. 2016, 3, 21.
S. Seiffert, Angew. Chem., Int. Ed. Engl. 2013, 52, 11462.
a) P. Guo, D. Liu, K. Subramanyam, B. Wang, J. Yang, J. Huang, D. T. Auguste, M. A. Moses, Nat. Commun. 2018, 9, 130;
b) M. Z. A. C. Anselmo, S. Kumar, D. R. Vogus, S. Menegatti, M. E. Helgeson, S. Mitragotri, ACS Nano 2015, 9, 3169;
c) Y. Hui, X. Yi, F. Hou, D. Wibowo, F. Zhang, D. Zhao, H. Gao, C. X. Zhao, ACS Nano 2019, 13, 7410.
S. Soni, A. K. Babbar, R. K. Sharma, A. Maitra, J. Drug Targeting 2006, 14, 87.
S. Singh, N. Drude, L. Blank, P. B. Desai, H. Königs, S. Rütten, K. J. Langen, M. Möller, F. M. Mottaghy, A. Morgenroth, Adv. Healthcare Mater. 2021, 10, 2100812.
S. Singh, B. Bingöl, A. Morgenroth, F. M. Mottaghy, M. Möller, J. Schmaljohann, Macromol. Rapid Commun. 2013, 34, 562.
N. Drude, S. Singh, O. H. Winz, M. Moller, F. M. Mottaghy, A. Morgenroth, Biomacromolecules 2017, 18, 2489.
N. Drude, O. H. Winz, F. M. Mottaghy, M. Roller, H. Konigs, M. Moller, S. Singh, A. Morgenroth, Small 2018, 14, 1704093.
J. Lux, A. G. White, M. Chan, C. J. Anderson, A. Almutairi, Theranostics 2015, 5, 277.
S. Lee, S. W. Kang, J. H. Ryu, J. H. Na, D. E. Lee, S. J. Han, C. M. Kang, Y. S. Choe, K. C. Lee, J. F. Leary, K. Choi, K. H. Lee, K. Kim, Bioconjugate Chem. 2014, 25, 601.
a) A. Soleimani, F. Martínez, V. Economopoulos, P. J. Foster, T. J. Scholl, E. R. Gillies, J. Mater. Chem. B 2013, 1, 1027;
b) C. V. Gheran, G. Rigaux, M. Callewaert, A. Berquand, M. Molinari, F. Chuburu, S. N. Voicu, A. Dinischiotu, Nanomaterials 2018, 8, 201;
c) C.-K. Lim, A. Singh, J. Heo, D. Kim, K. E. Lee, H. Jeon, J. Koh, I.-C. Kwon, S. Kim, Biomaterials 2013, 34, 6846;
d) M. Chan, J. Lux, T. Nishimura, K. Akiyoshi, A. Almutairi, Biomacromolecules 2015, 16, 2964;
e) Y. Cao, L. Xu, Y. Kuang, D. Xiong, R. Pei, J. Mater. Chem. B 2017, 5, 3431.
J. S. Brenner, D. C. Pan, J. W. Myerson, O. A. Marcos-Contreras, C. H. Villa, P. Patel, H. Hekierski, S. Chatterjee, J.-Q. Tao, H. Parhiz, Nat. Commun. 2018, 9, 1410.
a) J. F. Nijsen, B. A. Zonnenberg, J. R. Woittiez, D. W. Rook, I. A. Swildens-van Woudenberg, P. P. van Rijk, A. D. van het Schip, Eur. J. Nucl. Med. 1999, 26, 699;
b) A. Van Der Gucht, M. Jreige, A. Denys, P. Blanc-Durand, A. Boubaker, A. Pomoni, P. Mitsakis, M. Silva-Monteiro, S. Gnesin, M. N. Lalonde, J. Nucl. Med. 2017, 58, 1334.
B. Ouyang, W. Poon, Y.-N. Zhang, Z. P. Lin, B. R. Kingston, A. J. Tavares, Y. Zhang, J. Chen, M. S. Valic, A. M. Syed, Nat. Mater. 2020, 19, 1362.
W. Lee, G. Il An, H. Park, S. Sarkar, Y. S. Ha, P. T. Huynh, A. Bhise, N. Bhatt, H. Ahn, D. N. Pandya, ACS Nano 2021, 15, 17348.
a) A. Goel, S. Augustine, J. Baranowska-Kortylewicz, D. Colcher, B. J. Booth, G. Pavlinkova, M. Tempero, S. K. Batra, Clin. Cancer Res. 2001, 7, 175;
b) O. Lindén, C. Hindorf, E. Cavallin-Ståhl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, J. Tennvall, Clin. Cancer Res. 2005, 11, 5215;
c) A. J. Ocean, K. L. Pennington, M. J. Guarino, A. Sheikh, T. Bekaii-Saab, A. N. Serafini, D. Lee, M. W. Sung, S. A. Gulec, S. J. Goldsmith, Cancer 2012, 118, 5497.